Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired…
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
First NCFB patient dosed in Phase IIa study of RESP-X
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex invites you to Alderley Park's 10th Anniversary SciTech Extravaganza
Saturday 14 September, 10:00am - 3:00pm Come and join us in Glasshouse at…
Infex to present RESP-X Phase I data at ERS Congress
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex strengthens its senior leadership team
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex webinar - broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the…
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex CSO invited to speak at GARDP REVIVE Webinar
On 27th June, Dr Victoria Savage, Chief Scientific Officer for Infex…
